Car T Cell Therapy

Melbourne wants to become an mRNA hub, with investments from both BioNTech & Moderna. Pic: getty/walterbibikow

BioNTech to build mRNA center in Australia

By Rachel Arthur

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

© GettyImages/Design Cells

Milestone approval for Kite CAR-T cell therapy

By Jane Byrne

The US FDA has approved Yescarta, Kite's CAR-T cell therapy, for initial treatment in adults with large B-cell lymphoma (LBCL) that is refractory to one prior therapy or that relapses within 12 months of first-line chemoimmunotherapy.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers